Translate Bio announced that Rand Sutherland, MD, MPH, has been appointed President effective March 22, 2021, Dr. Sutherland's first day of employment. Dr. Sutherland brings 20 years of combined industry, medical and academic expertise in pulmonary and rare diseases to this role. His most recent industry experience includes strategic and operational direction of Global Medical Affairs at Sanofi Genzyme, where he led the teams focused on medical evidence generation and engagement across the unit’s specialty care therapeutic areas. While in academia, he served as Chief of Pulmonary and Critical Care Medicine at National Jewish Health, directing clinical and research efforts focused on improving care for patients with a wide range of rare and complicated pulmonary diseases. As President of Translate Bio, Dr. Sutherland will be responsible for research and development, corporate development and program management, including portfolio and pipeline strategy with a focus on prioritizing and optimizing the Company’s R&D opportunities while evaluating corporate and business development prospects. Prior to joining Translate Bio, Dr. Sutherland served for seven years at Sanofi Genzyme, serving most recently as Global Head of Medical Affairs, and prior to that Head of the Rare Diseases Development therapeutic area.